Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) insider Joanne Curley sold 1,545 shares of the firm’s stock in a transaction that occurred on Wednesday, June 22nd. The shares were sold at an average price of $15.01, for a total value of $23,190.45. Following the completion of the sale, the insider now owns 23,688 shares in the company, valued at $355,556.88. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Joanne Curley also recently made the following trade(s):
- On Friday, June 17th, Joanne Curley sold 5,887 shares of Vera Therapeutics stock. The shares were sold at an average price of $15.04, for a total value of $88,540.48.
Shares of VERA traded down $0.60 during trading hours on Thursday, hitting $13.62. 43,567 shares of the company were exchanged, compared to its average volume of 100,045. The company has a market capitalization of $368.63 million and a PE ratio of -6.22. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.90 and a quick ratio of 7.90. The firm has a fifty day simple moving average of $16.75 and a 200-day simple moving average of $20.24. Vera Therapeutics, Inc. has a one year low of $12.28 and a one year high of $37.11.
Institutional investors have recently modified their holdings of the company. UBS Group AG acquired a new stake in shares of Vera Therapeutics in the first quarter worth $47,000. American International Group Inc. boosted its position in shares of Vera Therapeutics by 29.2% in the first quarter. American International Group Inc. now owns 6,794 shares of the company’s stock worth $160,000 after buying an additional 1,535 shares during the period. New York State Common Retirement Fund boosted its position in shares of Vera Therapeutics by 445.8% in the fourth quarter. New York State Common Retirement Fund now owns 6,549 shares of the company’s stock worth $175,000 after buying an additional 5,349 shares during the period. MetLife Investment Management LLC acquired a new stake in shares of Vera Therapeutics in the first quarter worth $209,000. Finally, Rhumbline Advisers acquired a new stake in shares of Vera Therapeutics in the first quarter worth $244,000. 78.57% of the stock is owned by institutional investors and hedge funds.
Several analysts recently commented on the company. Lifesci Capital restated an “outperform” rating on shares of Vera Therapeutics in a research report on Monday, March 28th. Wedbush started coverage on Vera Therapeutics in a research report on Monday, April 18th. They set an “outperform” rating and a $32.00 price target on the stock. Finally, HC Wainwright started coverage on Vera Therapeutics in a research report on Monday, May 2nd. They set a “buy” rating and a $35.00 price target on the stock.
Vera Therapeutics Company Profile (Get Rating)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
- Get a free copy of the StockNews.com research report on Vera Therapeutics (VERA)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.